Anthem Biosciences up 2% as ₹275 cr loan converted into equity

Anthem Biosciences Limited, engaged in contract research, development, and manufacturing of complex APIs, biologics like probiotics and enzymes, peptides, biosimilars, plus biotech services for global pharma clients, jumped 2.13% to ₹710.75 after executing a First Amendment to convert an additional ₹275 crore loan into equity shares of its wholly-owned subsidiary Neoanthem Lifesciences.